Merit Medical Systems EBIT 2012-2026 | MMSI
Merit Medical Systems ebit from 2012 to 2026. Ebit can be defined as earnings before interest and taxes.
|
Merit Medical Systems Annual EBIT (Millions of US $) |
|
|---|---|
| 2025 | $185 |
| 2024 | $156 |
| 2023 | $124 |
| 2022 | $88 |
| 2021 | $61 |
| 2020 | $-2 |
| 2019 | $15 |
| 2018 | $59 |
| 2017 | $33 |
| 2016 | $35 |
| 2015 | $38 |
| 2014 | $40 |
| 2013 | $28 |
| 2012 | $30 |
| 2011 | $33 |
|
Merit Medical Systems Quarterly EBIT (Millions of US $) |
|
|---|---|
| 2026-03-31 | $44 |
| 2025-12-31 | $54 |
| 2025-09-30 | $43 |
| 2025-06-30 | $47 |
| 2025-03-31 | $41 |
| 2024-12-31 | $37 |
| 2024-09-30 | $37 |
| 2024-06-30 | $46 |
| 2024-03-31 | $36 |
| 2023-12-31 | $34 |
| 2023-09-30 | $35 |
| 2023-06-30 | $29 |
| 2023-03-31 | $26 |
| 2022-12-31 | $30 |
| 2022-09-30 | $19 |
| 2022-06-30 | $23 |
| 2022-03-31 | $15 |
| 2021-12-31 | $22 |
| 2021-09-30 | $16 |
| 2021-06-30 | $9 |
| 2021-03-31 | $14 |
| 2020-12-31 | $16 |
| 2020-09-30 | $0 |
| 2020-06-30 | $-19 |
| 2020-03-31 | $1 |
| 2019-12-31 | $-3 |
| 2019-09-30 | $-3 |
| 2019-06-30 | $12 |
| 2019-03-31 | $10 |
| 2018-12-31 | $14 |
| 2018-09-30 | $21 |
| 2018-06-30 | $15 |
| 2018-03-31 | $9 |
| 2017-12-31 | $13 |
| 2017-09-30 | $1 |
| 2017-06-30 | $13 |
| 2017-03-31 | $6 |
| 2016-12-31 | $13 |
| 2016-09-30 | $3 |
| 2016-06-30 | $12 |
| 2016-03-31 | $8 |
| 2015-12-31 | $8 |
| 2015-09-30 | $9 |
| 2015-06-30 | $12 |
| 2015-03-31 | $9 |
| 2014-12-31 | $14 |
| 2014-09-30 | $12 |
| 2014-06-30 | $7 |
| 2014-03-31 | $6 |
| 2013-12-31 | $11 |
| 2013-09-30 | $8 |
| 2013-06-30 | $7 |
| 2013-03-31 | $2 |
| 2012-12-31 | $4 |
| 2012-09-30 | $9 |
| 2012-06-30 | $8 |
| 2012-03-31 | $8 |
| 2011-12-31 | $6 |
| 2011-09-30 | $7 |
| 2011-06-30 | $11 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $4.072B | $1.516B |
| Merit Medical Systems, Inc. provides various peripheral and cardiac intervention products to cure cardiac conditions specific to interventional cardiology and electrophysiology. The company offers products focused in five core product groups: peripheral intervention, cardiac intervention, interventional oncology and spine, cardiovascular and critical care as well as endoscopy. However, the company operates in two revenue segments: Cardiovascular and Endoscopy Devices. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $106.025B | 23.03 |
| Cardinal Health (CAH) | United States | $50.715B | 22.43 |
| Becton Dickinson (BDX) | United States | $43.913B | 11.10 |
| West Pharmaceutical Services (WST) | United States | $18.493B | 35.19 |
| Straumann Holding AG (SAUHY) | Switzerland | $16.902B | 0.00 |
| Cooper (COO) | United States | $13.894B | 16.52 |
| Align Technology (ALGN) | United States | $12.400B | 21.09 |
| Henry Schein (HSIC) | United States | $8.645B | 15.16 |
| DENTSPLY SIRONA (XRAY) | United States | $2.339B | 7.36 |
| STAAR Surgical (STAA) | United States | $1.309B | 0.00 |
| CONMED (CNMD) | United States | $1.107B | 7.97 |
| Pro-Dex (PDEX) | United States | $0.165B | 19.65 |
| Lifevantage (LFVN) | United States | $0.053B | 5.46 |
| Axe Compute (AGPU) | United States | $0.022B | 0.00 |